Wegovy vs Saxenda: Real-World Evidence Comparison

Semaglutide (Wegovy) and liraglutide (Saxenda) are both glucagon-like peptide-1 (GLP-1) receptor agonists made by Novo Nordisk, but they are chemically distinct molecules with different injection schedules, titration lengths, and regulatory histories. Semaglutide is also sold as Ozempic and Rybelsus for type 2 diabetes at different doses; liraglutide is also sold as Victoza for diabetes at a lower dose (1.8 mg) than Saxenda's 3 mg. Confusing the weight-management formulation with the diabetes formulation of the same molecule is a common source of dosing errors, so a prescriber, not a comparison article, should confirm which product and dose a specific patient is meant to use.

The core comparison, stated plainly

In head-to-head-quality randomized trials, semaglutide 2.4 mg produced roughly twice the mean weight loss of liraglutide 3 mg (14.9% versus 8.0% of body weight, in trials of different duration and design) [1][2]. Real-world registry and claims data generally track this direction, though the size of the gap outside controlled trials is less precisely established. Only semaglutide 2.4 mg has a dedicated cardiovascular outcomes trial and FDA-recognized cardiovascular risk-reduction indication in adults with obesity or overweight and established cardiovascular disease [8][6]. Liraglutide's cardiovascular evidence comes from a lower-dose diabetes formulation tested in a different population, which limits how far it can be extrapolated to Saxenda users without diabetes [9].

What the pivotal trials actually show

STEP-1, published in the New England Journal of Medicine in 2021 (N=1,961 adults without diabetes), found that semaglutide 2.4 mg produced a mean weight loss of 14.9% of body weight at 68 weeks versus 2.4% with placebo, with 86.4% of participants reaching at least 5% weight loss [1].

The SCALE Obesity and Prediabetes trial (N=3,731, NEJM 2015) is the pivotal trial for liraglutide 3 mg. Participants lost a mean of 8.0% of body weight at 56 weeks versus 2.6% with placebo, and 63.2% reached at least 5% weight loss [2]. That result was meaningful relative to older options available at the time, such as orlistat or phentermine-topiramate, though it is smaller than what semaglutide later demonstrated.

STEP-1 and SCALE are not perfectly comparable studies. They ran for different lengths (68 versus 56 weeks), used different titration schedules, and enrolled populations with somewhat different baseline characteristics. Semaglutide's longer plasma half-life (approximately 165 hours, versus roughly 13 hours for liraglutide) is what allows once-weekly rather than once-daily dosing and is one plausible mechanistic contributor to its stronger effect, though the trials were not designed to isolate half-life as the cause of the efficacy difference [3].

Real-world evidence: how the trial gap holds up outside clinical trials

Randomized trials enroll closely monitored, often more adherent participants, so real-world data matter for judging whether trial results generalize.

A Danish national registry analysis of adults who started semaglutide 2.4 mg or liraglutide 3 mg between 2021 and 2022 reported higher mean weight loss and higher 12-month treatment persistence in the semaglutide group [4]. This is observational, registry-based evidence, not a randomized comparison, so it can show association and real-world persistence patterns but cannot fully control for why patients or prescribers chose one drug over the other.

Claims-based and cohort analyses of semaglutide response in people with overweight or obesity have also been published [5]. That particular source describes outcomes among semaglutide users rather than a controlled head-to-head comparison against liraglutide users, so a precise numeric estimate of how much more likely semaglutide patients are to reach 10% weight loss compared with liraglutide patients cannot be stated confidently from this source alone. Readers and clinicians who need that specific comparative figure should verify it against a study designed as a direct semaglutide-versus-liraglutide comparison before relying on it.

Patient-reported quality-of-life measures (IWQOL-Lite-CT) improved with semaglutide in the STEP-1 substudy, and SCALE also showed quality-of-life improvement with liraglutide, consistent in direction with the smaller weight loss seen with liraglutide [1][2].

Which patient fits which drug: a scenario-based decision guide

Body-weight percentages and half-lives do not tell a specific patient what to do. The table below reorganizes the same evidence around the decisions clinicians and patients actually face.

Providers and patients should use this table as a basis for discussing treatment options, recognizing that individual circumstances require personalized dosing and therapeutic choices.

Dosing and titration: the practical day-to-day difference

Wegovy uses a 16-week titration: 0.25 mg weekly for four weeks, then 0.5 mg, 1.0 mg, and 1.7 mg, each for four weeks, before reaching the 2.4 mg maintenance dose at week 17. The FDA label allows staying at a lower tolerated dose if 2.4 mg is not tolerated [6]. About 7% of STEP-1 participants discontinued due to adverse events.

Saxenda starts at 0.6 mg once daily for one week and increases by 0.6 mg weekly until reaching 3 mg at week 5, a much faster ramp than Wegovy's. Approximately 9.8% of SCALE participants discontinued due to adverse events [2].

Wegovy is a once-weekly prefilled pen; the injection day can shift by up to two days without a clinically meaningful effect. Saxenda requires daily injection, roughly 365 injections a year versus 52 for Wegovy. Lower injection frequency is a plausible contributor to the higher persistence seen for semaglutide in the Danish registry data, though persistence is also affected by cost, side effects, and access, so injection frequency alone should not be treated as the full explanation [4].

Any change in dose, brand, or titration schedule should be made with a prescriber, not self-directed. This article describes what the approved schedules look like; it does not provide an individualized dosing plan.

Side effects: what overlaps and what differs

Both drugs share the class-level GLP-1 GI side-effect pattern: nausea, vomiting, diarrhea, and constipation are the most common complaints, driven by receptor activity in the gut.

In STEP-1, nausea occurred in 44% and vomiting in 24.5% of semaglutide-treated participants [1]. In SCALE, nausea occurred in 39.3% and vomiting in 15.7% of liraglutide-treated participants [2]. Saxenda's nausea tends to peak early and ease off after the first few weeks; Wegovy's slower, stepwise titration means GI symptoms can reappear with each dose increase over 16 weeks. Individual variation is large, and neither pattern is reliably more tolerable across all patients.

Both agents carry an FDA boxed warning regarding thyroid C-cell tumors observed in animal studies and must be avoided in patients with personal or familial medullary thyroid carcinoma or multiple endocrine neoplasia type 2 [6][7]. Acute pancreatitis has occurred in patients taking either agent, though causality remains uncertain; counseling should emphasize immediate medication discontinuation and emergency evaluation for severe or unrelenting abdominal pain. Accelerated weight loss from either medication elevates gallstone formation risk; the STEP-1 trial documented cholelithiasis in 2.6% of semaglutide-treated subjects versus 1.2% receiving placebo, with SCALE yielding a similar observation. At subsequent appointments, clinicians should specifically inquire about biliary discomfort, including right upper quadrant pain triggered by high-fat meals.

Cardiovascular evidence: the clearest point of separation

The SELECT trial (N=17,604 adults with BMI 27 or above, established cardiovascular disease, and no diabetes) found that semaglutide 2.4 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke by 20% versus placebo (hazard ratio 0.80; 95% CI 0.72 to 0.90; P<0.001) over a mean follow-up of 33.3 months [8]. The FDA subsequently expanded Wegovy's label in March 2024 to include reduction of cardiovascular events in adults with obesity or overweight and established cardiovascular disease [6]; this labeling status should be reconfirmed against the current FDA label if this article is read well after that date.

Liraglutide's cardiovascular outcomes evidence comes from the LEADER trial, which tested liraglutide 1.8 mg (marketed as Victoza, the diabetes-dose formulation) in 9,340 people with type 2 diabetes and high cardiovascular risk, showing a 13% reduction in major adverse cardiovascular events (hazard ratio 0.87; 95% CI 0.78 to 0.97) [9]. Saxenda, the 3 mg weight-management dose, does not have a published dedicated cardiovascular outcomes trial in a non-diabetic obesity population. Extrapolating LEADER's result to Saxenda users without diabetes is not established and should not be presented to a patient as equivalent evidence.

For a patient with established cardiovascular disease considering either drug, this is the single largest evidence-quality difference between the two options.

Cost, coverage, and supply: what is dated information

Approximate US list prices in early 2025 were near $1,349 per month for Wegovy and near $1,400 per month for Saxenda. These figures change and should be verified directly with the manufacturer or a pharmacy before being used to make a decision. Manufacturer savings programs have historically reduced out-of-pocket costs substantially for eligible commercially insured patients, with different terms for uninsured patients; exact current savings-card amounts and eligibility rules should be checked on the manufacturer's site rather than assumed from this or any other article, since these programs change income thresholds and amounts over time and typically exclude Medicare and Medicaid beneficiaries.

Coverage varies by plan. Some commercial insurers have shifted toward covering Wegovy preferentially following its 2024 cardiovascular label expansion, but this is plan-dependent and not universal. Medicare Part D has historically excluded obesity-only medications; whether Wegovy's cardiovascular indication changes that for any individual Medicare beneficiary depends on current CMS policy at the time of reading, which should be verified rather than assumed.

Wegovy experienced supply shortages from 2022 through much of 2023. The FDA's shortage listing for semaglutide 2.4 mg injection was removed in late 2023, with supply reported as largely normalized from early 2024 [10]; current status should be checked against the live FDA shortage database rather than this summary, since shortages can recur.

Switching between the two drugs

Switching is a decision for a prescriber, informed by tolerability, response, cost, and access, not a self-directed change.

Guidance used during the 2022 to 2023 Wegovy shortage from obesity medicine professional groups described liraglutide 3 mg as a reasonable temporary bridge when semaglutide was unavailable, with attention to liraglutide's lower per-milligram receptor potency when adjusting expectations [11]. The exact wording of that guidance should be confirmed against the original position statement before it is quoted directly; this article paraphrases the substance rather than reproducing an exact quotation, because the precise language could not be verified from the source material available for this draft.

Patients who switch from semaglutide to liraglutide, for cost or access reasons, should generally expect a smaller weight-loss effect going forward, consistent with liraglutide's own trial and registry results, rather than expecting to maintain semaglutide-level results on a different drug [2][4]. A specific percentage-point estimate for weight regain or loss attributable specifically to the switch itself, as opposed to the underlying difference between the drugs, was not identified in verifiable source material for this draft and should not be stated as a precise figure without a study designed to measure it directly.

Most obesity medicine guidance favors moving from liraglutide to semaglutide, rather than the reverse, when a patient is not reaching an adequate response on liraglutide's maximum tolerated dose. A 2023 consensus statement from the American Association of Clinical Endocrinology addresses obesity pharmacotherapy escalation in general terms [12]; readers should consult the primary document directly for its exact criteria and wording rather than relying on a paraphrase here, since the earlier version of this article misattributed similar language to a different professional body and that specific quotation could not be verified.

When a prescriber decides to move a patient from liraglutide to semaglutide, common practice (reflected in the respective FDA labels) is to stop the daily liraglutide dose and begin semaglutide at its lowest starting dose on the next scheduled injection day, without a mandatory washout, then follow the standard semaglutide titration schedule while monitoring weight and GI symptoms [6][7]. This description is general information about how such a transition is typically structured; it is not an individualized dosing instruction, and any actual switch should be planned and monitored by the prescribing clinician.

What happens after stopping either drug

Neither drug produces durable weight loss after it is stopped; regain is the expected pattern for both.

STEP-4 (N=803) followed participants who had already lost weight on semaglutide 2.4 mg for 20 weeks. Those randomized to stop semaglutide regained an average of 6.9 percentage points of body weight over the following 48 weeks, while those who continued treatment lost an additional 7.9% [13]. By week 68, the gap in body weight between the two groups was close to 14 percentage points.

Longer-term liraglutide discontinuation data are less centrally documented in the sources available for this comparison; the SCALE program is the primary trial source for liraglutide's efficacy, and any specific regain percentage after stopping liraglutide should be checked against a dedicated discontinuation study before being stated as a precise figure [2].

Patients who need to stop either drug, for cost, tolerability, or a planned surgery, benefit from having a structured dietary and behavioral plan in place before stopping rather than after.

Evidence boundary: what is established, what is not

Established, from randomized trial and regulatory evidence: semaglutide 2.4 mg produces greater mean weight loss than liraglutide 3 mg in their respective pivotal trials; semaglutide 2.4 mg has a dedicated cardiovascular outcomes trial (SELECT) and an FDA-recognized cardiovascular indication in adults with obesity or overweight and established cardiovascular disease; both drugs carry an FDA boxed warning for thyroid C-cell tumor risk; weight regain after stopping semaglutide is documented in a randomized discontinuation trial (STEP-4).

Plausible but not rigorously established: that the size of the real-world weight-loss gap between the two drugs matches the gap seen in their differently-designed pivotal trials; that liraglutide's cardiovascular benefit in diabetes (LEADER) transfers to non-diabetic Saxenda users; that injection frequency alone explains the persistence difference seen in registry data, independent of cost and side effects.

Not established from the material reviewed for this article: a precise real-world percentage difference in the odds of reaching 10% weight loss between semaglutide and liraglutide users from a study specifically designed as a head-to-head comparison; the exact wording of professional society statements quoted in earlier versions of comparison content on this topic, which should be verified against primary documents before being quoted directly; current savings-program dollar amounts and Medicare coverage rules, both of which change over time.

When to seek care rather than rely on this comparison

Severe or persistent abdominal pain, signs of gallbladder disease (right upper quadrant pain, fever, jaundice), a new neck lump or hoarseness, or any suspicion of an allergic reaction after either drug warrants prompt medical evaluation rather than waiting for a scheduled follow-up. Neither Wegovy nor Saxenda should be started, stopped, or switched without involving the prescribing clinician.

Head-to-head summary table